REVB

Revelation BiosciencesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$1.40

+32.1% vs current

Most likely

Base case

45%

Probability

Target price

$0.85

-19.8% vs current

B-

Bear case

30%

Probability

Target price

$0.45

-57.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

The post-earnings setup is still tentative because coverage is thin and no trustworthy post-print analyst target or rating revision was available in the packet. With a $1.02 anchor on May 7, 2026 and a negative deterministic prior, the May 7 filing is best treated as a monitoring update around runway, going-concern language, and AKI execution rather than a confirmed thesis turn.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-08-31catalystPost-earnings cash update reduced immediate liquidity pressure but did not remove financing riskHigh impact

The May 7 8-K confirms Revelation furnished Q1 2026 financial results, and the Q1 10-Q remains the controlling primary-source risk marker: current cash was still described as insufficient to sustain operations for one year from issuance, with substantial doubt about going concern. The earnings follow-up therefore remains financing-sensitive rather than a clean liquidity reset [#8-K-2026-05-07] [#10-Q-2026-05-07].

2026-09-30eventGEM-AKI Phase 2/3 study-start progress remains the main upside checkpointHigh impact

The prior baseline and 2025 10-K support that management planned during 2026 to build study infrastructure, engage a CRO, manufacture blinded drug and placebo, and move toward starting the GEM-AKI adaptive Phase 2/3 study as feasible. Until Revelation confirms trial initiation or enrollment, this remains a monitoring catalyst rather than a proven rerating event [#10-K-2026-02-26] [#8-K-2026-05-07].

2026-12-31catalystGEM-CKD toxicology and repeat-dose preparation remain secondary pipeline proof pointsHigh impact

The 2025 10-K says Revelation intends during 2026 to conduct preclinical toxicology studies to support a repeat-dose Phase 2 CKD study. That could help validate broader Gemini platform optionality, but it is earlier stage and lower visibility than GEM-AKI study-start progress [#10-K-2026-02-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology